AbCellera Biologics, Inc. launches an IPO.

An IPO of AbCellera Biologics, Inc. (ABCL) will take place on December 10, 2020. AbCellera Biologics is a comprehensive artificial intelligence drug discovery platform that searches and analyzes a database of natural immune systems to find antibodies that can be used for drug development. Antibodies, which are proteins made by the natural immune system to fight infection and disease, are among the fastest growing class of drugs and are used in many therapeutic areas, including cancer, inflammation, neurodegeneration and many others. In 2019 antibody-based therapies were sold over $140 billion worldwide and represented five of the top 10 best-selling therapies.
The listed bookrunners of the IPO are Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets.